SELLAS Life Sciences Group, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
SELLAS Life Sciences Group, Inc. (SLS) had Lessee, Operating Lease, Liability, to be Paid, Year One of $477.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $477.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Year One $477.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $635.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $477.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2026-06-30 | $477.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $477.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $635.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $477.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $477.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $477.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $635.00K 10-K · filed 2025-03-20 |
| 2024-09-30 | $477.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $477.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $477.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $533.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $533.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $533.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $533.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $518.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $518.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $518.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $518.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $311.00K 10-K · filed 2022-03-31 |
| 2021-09-30 | $311.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $311.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $311.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $303.00K 10-K · filed 2021-03-23 |
| 2020-09-30 | $302.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $302.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |